Annovis Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Annovis Bio, Inc. (ANVS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.34 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $3.34, a 140.29% increase year-over-year.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.62.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $1.80, a 59.73% decline year-over-year.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $1.39, a 72.85% decline year-over-year.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.76, a 65.89% decline from fiscal 2024.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.16, a 30.18% decline from fiscal 2023.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $7.39, a 44.18% decline from fiscal 2022.
- Annovis Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $13.24, a 51.20% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.34 10-Q · filed 2026-08-14 | $3.30 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | $2.62 10-Q · filed 2026-05-15 | |||
| 2025-12-31 | $1.76 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $1.80 10-Q · filed 2025-11-12 | $1.76 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $1.39 10-Q · filed 2026-08-14 | $1.39 10-Q · filed 2026-08-14 | ||
| 2024-12-31 | $5.16 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $4.47 10-Q · filed 2025-11-12 | $5.04 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $5.12 10-Q · filed 2025-08-12 | $5.12 10-Q · filed 2025-08-12 | ||
| 2023-12-31 | $7.39 10-K · filed 2025-03-21 | |||
| 2022-12-31 | $13.24 10-K · filed 2024-03-29 | |||
| 2021-12-31 | $27.13 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $2.19 10-K · filed 2022-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |